Bloomberg Featured Podcasts and New Shows

The Bloomberg Advantage: Gordon on Pfizer Deal for Medivation

August 22, 20168 min
(Bloomberg) -- The Bloomberg Advantage with Carol Massar and Cory Johnson.

GUEST:
Erik Gordon
Professor
Ross School of Business at the University of Michigan
Discussing Pfizer beating out a group of rivals after months of jockeying to buy Medivation and its blockbuster cancer drug for $14 billion.

Chat About The Bloomberg Advantage: Gordon on Pfizer Deal for Medivation

For You